Insider Activity at Amgen: A Close‑Read of Bradway’s Recent Deal
Transaction Details
Amgen’s most recent Form 4 filing discloses that Chairman, CEO and President Bradway Robert A acquired 119,782 shares of the company’s common stock on March 4, 2026. The purchase price of $156.35 per share is markedly below the market price of $369.51 on the same day, reflecting a non‑market exercise of stock options that vested in early May. By completing this transaction, Bradway increased his post‑transaction holdings to 576,928 shares, representing roughly 0.28 % of Amgen’s outstanding equity.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-03-04 | Bradway Robert A (Chairman, CEO and President) | Buy | 119,782.00 | 156.35 | Common Stock |
| 2026-03-04 | Bradway Robert A (Chairman, CEO and President) | Sell | 84,285.00 | 379.27 | Common Stock |
| N/A | Bradway Robert A (Chairman, CEO and President) | Holding | 90,000.00 | N/A | Common Stock |
| 2026-03-04 | Bradway Robert A (Chairman, CEO and President) | Sell | 119,782.00 | N/A | Nqso (Right to Buy) |
The transaction is part of a broader wave of insider purchases that week, with several executives buying shares in a coordinated effort that signals confidence in Amgen’s near‑term outlook.
Implications for Investors
A substantial insider buy at a deep discount can be interpreted as management’s conviction that the stock is undervalued. Amgen’s recent dividend declaration for Q2 2026 and the upcoming shareholder meeting reinforce this perspective. Despite the purchase, market sentiment remains muted—social media sentiment is 13 points negative and overall buzz is at 76 %—and the stock experienced a modest weekly decline of –4.81 %.
For long‑term holders, Bradway’s action may reinforce the narrative that Amgen’s biotech pipeline, underpinned by a market cap of $204 B and a P/E ratio of 25.2, remains robust. For short‑term traders, it is important to note that the purchase represents a small fraction of total shares outstanding, and its impact on price movement is expected to be limited.
Bradway Robert A: Transaction Profile
Bradway’s insider‑trading history shows a disciplined, incremental buying pattern. Over the past 18 months he has executed four major purchases of common stock, each accompanied by the acquisition of non‑qualified stock options (Nqso) that are exercised at later dates. In May 2025 he bought 13,311 shares and 86,042 Nqsos; in March 2026 he purchased 42,657 shares. His holdings have hovered around 90,000 shares, indicating a long‑term commitment to Amgen. Unlike other executives who have sold shares—such as Santos Esteban’s recent sale of 30,501 shares—Bradway’s consistent buying suggests confidence in the company’s strategic direction, particularly its focus on novel therapeutics and upcoming product launches.
Outlook for Amgen
The convergence of insider buying, a declared dividend, and the scheduled conference appearance by CFO Peter Griffith points to an active period of shareholder value creation. Bradway’s purchase adds credibility to Amgen’s earnings guidance and may encourage other investors to view the stock as a defensive play amid volatility in the healthcare sector. While the 52‑week high remains above the current price, the recent downward trend and high market cap position Amgen as a stable yet mature player in biotechnology.
Investors seeking exposure to established biopharma should weigh the potential for dividend income against the company’s modest upside potential, given its current valuation metrics.
